ישראל - עברית - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril

ישראל - עברית - Ministry of Health

unipharm ltd, israel - sacubitril/valsartan as sodium salt complex as sodium salt complex - sacubitril/valsartan as sodium salt complex as sodium salt complex 49/51 mg - valsartan and sacubitril

ישראל - עברית - Ministry of Health

unipharm ltd, israel - sacubitril/valsartan as sodium salt complex as sodium salt complex - טבליות מצופות - sacubitril/valsartan as sodium salt complex as sodium salt complex 97/103 mg - valsartan and sacubitril

ישראל - עברית - Ministry of Health

unipharm ltd, israel - sacubitril/valsartan as sodium salt complex as sodium salt complex - טבליות מצופות - sacubitril/valsartan as sodium salt complex as sodium salt complex 24/26 mg - valsartan and sacubitril

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - nitrofurantoin anhydrous; nitrofurantoin macrocrystals - קפסולות - nitrofurantoin anhydrous 75 mg; nitrofurantoin macrocrystals 25 mg - nitrofurantoin

ישראל - עברית - Ministry of Health

אורג'ניקס בע"מ - צוות טכני - in vitro, visually read, qualitative immunoassay for the simultaneous detection of free non immunocomplexed hiv-1 p24 antigen (ag) and antibodies (ab) to hiv-1 and hiv-2 in human blood.

ישראל - עברית - Ministry of Health

lapidot medical import and marketing ltd - iron sucrose - תמיסה להזרקה - iron sucrose 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro- intestinal malobsorption which rules our oral therapy, patients on dialysis treated with erythropoietin.

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*